Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 41

Sort by

Sort Order Select

Journal Articles

Long-Term Dosing in Sickle Cell Disease Subjects with GBT440, a Novel HbS Polymerization Inhibitor

Josh Lehrer-Graiwer, MDMPhil, FACC, Jo Howard, MB, BChir, Claire Jane Hemmaway, MD, Moji Awogbade, Paul Telfer, FRCPath,MD, Mark Layton, MB, FRCP, John B. Porter, MD, Timothy Mant, MB, FFPM, FRCP, Kobina Dufu, PhD, Athiwat Hutchaleelaha, PhD, Donna Oksenberg, PhD, Mira Patel, PhD, Margaret Eleanor Tonda, PharmD, Kenneth Bridges, MD, Eleanor Ramos, MD

Blood (2016) 128 (22): 2488.

https://doi.org/10.1182/blood.V128.22.2488.2488

Published: 2016

Journal Articles

Insights into Relationships Between Serum Ferritin and Liver Iron Concentration Trends during 12 Months of Iron Chelation Therapy with Deferasirox – a Post-Hoc Analysis from the Epic Study

John B Porter, MD, Mohsen Elalfy, MD, Ali T Taher, MD, Lee Lee Chan, MD, Szu-Hee Lee, MD, Pranee Sutcharitchan, MD, Yesim Aydinok, MD, Subhashish Chakravarty, PhD, Ali El-Ali, MD, Amal El-Beshlawy, MD/Professor

Blood (2014) 124 (21): 52.

https://doi.org/10.1182/blood.V124.21.52.52

Published: 2014

Journal Articles

Eltrombopag Mobilizes Intracellular Iron Stores at Concentrations Lower Than Those Required with Other Clinically Available Iron Chelators

Evangelia Vlachodimitropoulou Koumoutsea, MBBS, Nichola Cooper, MD, Bethan Psaila, Martha Sola-Visner, MD, John B Porter, MD

Blood (2014) 124 (21): 1353.

https://doi.org/10.1182/blood.V124.21.1353.1353

Published: 2014

Journal Articles

Multivariate Analysis Evaluating Potential Predictors of Cardiac T2* Where Cardiac Magnetic Resonance Imaging (CMR) Availability Is Limited

John B Porter, MD, Ali T Taher, MD PhD, Yesim Aydinok, MD, Amal El-Beshlawy, MD/Professor, Mohsen El-Alfy, MD, Ali El-Ali, MD, Subhashish Chakravarty, PhD, M Domenica Cappellini, MD

Blood (2014) 124 (21): 1366.

https://doi.org/10.1182/blood.V124.21.1366.1366

Published: 2014

Journal Articles

Relative Trends in Myocardial T2* Versus Myocardial Iron Concentration As Representations of Myocardial Iron Chelation Efficacy in Patients with β Thalassemia Major Treated with Deferasirox for up to 3 Years

John B Porter, MD, Ali T Taher, MD, Yesim Aydinok, MD, Amal El-Beshlawy, MD/Professor, Mohsen Elalfy, MD, Ali El-Ali, MD, Nathalie Barbier, M Domenica Cappellini, MD

Blood (2014) 124 (21): 4040.

https://doi.org/10.1182/blood.V124.21.4040.4040

Published: 2014

Journal Articles

Modeling Combination Chelation Regimes To Optimize Cellular Iron Removal and Explore Mechanisms Of Enhanced Chelation

Evangelia Vlachodimitropoulou, MBBS, Garbowski Maciej, MD, John B Porter, MD

Blood (2013) 122 (21): 2200.

https://doi.org/10.1182/blood.V122.21.2200.2200

Published: 2013

Journal Articles

Deferasirox Compared With Deferoxamine For The Removal Of Cardiac Iron In Patients With β-Thalassemia Major: 2-Year Data From The Cordelia Extension

Dudley J Pennell, MD, John B Porter, MD, Antonio Piga, MD, Yongrong Lai, MD, Amal El-Beshlawy, MD, Khawla Belhoul, MD, Mohsen Elalfy, MD, Akif Yesilipek, MD, Yurdanur Kilinç, MD, Antje Wegener, MD, Dany Habr, MD, Junwu Shen, PhD, Yesim Aydinok, MD

Blood (2013) 122 (21): 1018.

https://doi.org/10.1182/blood.V122.21.1018.1018

Published: 2013

Journal Articles

Association Of Cardiac Iron By T2* With Innate Immune Markers In Transfusion-Dependent Thalassemia Patients Undergoing Combined Chelation Therapy

Patrick B Walter, PhD, Annie Higa, BS, Vivian Ng, B.S., Marcela G Weyhmiller, PhD, Nick R Slater, Patricia Evans, PhD, John B Porter, MD, Nancy Sweeters, RN, PNP, Jackson Price, B.S., Alisha Manji, B.S., David Killilea, PhD, Ashutosh Lal, MD, Elliott Vichinsky, MD

Blood (2013) 122 (21): 3450.

https://doi.org/10.1182/blood.V122.21.3450.3450

Published: 2013

Journal Articles

Deferasirox–Deferoxamine Combination Therapy Reduces Cardiac Iron With Rapid Liver Iron Removal In Patients With Severe Transfusional Iron Overload (HYPERION)

Yesim Aydinok, MD, Antonis Kattamis, MD, M Domenica Cappellini, MD, Amal El-Beshlawy, MD, Raffaella Origa, MD, Mohsen Elalfy, MD, Yurdanur Kilinç, MD, Silverio Perrotta, MD, Zeynep Karakas, MD, Vip Viprakasit, MD, Dany Habr, MD, Antje Wegener, MD, Junwu Shen, PhD, John B Porter, MD

Blood (2013) 122 (21): 2257.

https://doi.org/10.1182/blood.V122.21.2257.2257

Published: 2013

Journal Articles

Determinants Of Tissue Iron Loading In Transfused and Non-Transfused β-Thalassemia and Sickle Cell Disease Patients – Biomarkers Of Iron Regulation and Inflammation

Patrick B Walter, PhD, Zahra Pakbaz, MD, Elizabeta Nemeth, PhD, Tomas Ganz, MD, PhD, John B Porter, MD, Patricia Evans, PhD, Kelsey M Houston, Roland Fischer, PhD, Marcela G Weyhmiller, PhD, Matt Herz, Bs, Jeffery L Miller, MD, Robert Hagar, MD, Lynne D Neumayr, MD, Elliott Vichinsky, MD, Paul Harmatz, MD

Blood (2013) 122 (21): 1017.

https://doi.org/10.1182/blood.V122.21.1017.1017

Published: 2013

Journal Articles

Spinal Artery Thrombosis: An Unrecognized Severe Complication in Thalassemia and Sickle Disorders

Maria Marzolini, Erika Poggiali, MD, Mohsin Badat, Elena Cassinerio, MD, Maria D Cappellini, John B. Porter, MD

Blood (2012) 120 (21): 1155.

https://doi.org/10.1182/blood.V120.21.1155.1155

Published: 2012

Journal Articles

Sildenafil Therapy in Patients with Thalassemia and an Elevated Tricuspid Regurgitant Jet Velocity (TRV) On Doppler Echocardiography At Risk for Pulmonary Hypertension: Report From the Thalassemia Clinical Research Network

Claudia R. Morris, MD, Hae-Young Kim, DrPH, John C Wood, MD, Felicia Trachtenberg, PhD, Elizabeth S Klings, MD, John B. Porter, MD, Nancy Sweeters, RN, PNP, Nancy F Olivieri, MD, Janet L. Kwiatkowski, MD, Sylvia Titi Singer, MD, Ali T Taher, MD, Ellis J. Neufeld, MD, PhD, Alexis A. Thompson, MD, MPH, Vandana Sachdev, M.D., Sandra K Larkin, MS, Jung H Suh, PhD, Frans A Kuypers, PhD, Elliott Vichinsky, MD

Blood (2012) 120 (21): 1023.

https://doi.org/10.1182/blood.V120.21.1023.1023

Published: 2012

Journal Articles

Innate Immune Cell Expression of Pattern Recognition Receptors From β-Thalassemia Patients During Intensive Combination Chelation Therapy

Patrick B Walter, PhD, Paul Harmatz, MD, Annie Higa, B.S., Vivian Ng, B.S., Marcela G Weyhmiller, PhD, Patricia Evans, PhD, John B. Porter, MD, Nancy Sweeters, RN, PNP, Jackson Price, B.S., Alisha Manji, B.S., David Killilea, PhD, Ashutosh Lal, MD, Elliott Vichinsky, MD

Blood (2012) 120 (21): 1025.

https://doi.org/10.1182/blood.V120.21.1025.1025

Published: 2012

Journal Articles

Deferasirox Continues to Reduce Iron Overload in Non-Transfusion-Dependent Thalassemia: A One-Year, Open-Label Extension to a One-Year, Randomized, Double-Blind, Placebo-Controlled Study (THALASSA)

Ali T Taher, MD, John B Porter, MD, Vip Viprakasit, MD, DPhil, Antonis Kattamis, MD, Suporn Chuncharunee, MD, Pranee Sutcharitchan, MD, Noppadol Siritanaratkul, MD, Renzo Galanello, MD, Zeynep Karakas, MD, Tomasz Lawniczek, MD, Dany Habr, MD, Jacqueline Ros, PhD, Zewen Zhu, M Domenica Cappellini, MD

Blood (2012) 120 (21): 3258.

https://doi.org/10.1182/blood.V120.21.3258.3258

Published: 2012

Journal Articles

Metabolomic Biomarkers As Predictors of Iron Load and Oxidative Damage in Iron Overloaded Thalassemia Patients

Farzana Sayani, MD FRCPC, Ying Zhang, MSc, Niloufar Abdolmohammadi, Anne Marie Lauf, Patricia Evans, PhD, John B. Porter, MD, Aalim Mahdi Weljie, PhD

Blood (2012) 120 (21): 3265.

https://doi.org/10.1182/blood.V120.21.3265.3265

Published: 2012

Journal Articles

Cardiopulmonary and Laboratory Profiling of Patients with Thalassemia At Risk for Pulmonary Hypertension: Report From the Thalassemia Clinical Research Network.

Claudia R. Morris, MD, Hae-Young Kim, DrPH, John C Wood, MD, Ph.D, Felicia Trachtenberg, PhD, Elizabeth S Klings, MD, John B. Porter, MD, Nancy Sweeters, RN, PNP, Nancy F Olivieri, MD, Janet L. Kwiatkowski, MD, Sylvia Titi Singer, MD, Ali T Taher, MD, Ellis J. Neufeld, MD, PhD, Alexis A. Thompson, MD, MPH, Sandra K Larkin, MS, Jung H Suh, PhD, Elliott Vichinsky, MD, Frans A Kuypers, PhD

Blood (2012) 120 (21): 2122.

https://doi.org/10.1182/blood.V120.21.2122.2122

Published: 2012

Journal Articles

A Multicenter, Randomized, Open-Label Trial Evaluating Deferasirox Compared with Deferoxamine for the Removal of Cardiac Iron in Patients with β-Thalassemia Major and Iron Overload (CORDELIA).

Dudley J Pennell, MD, John B Porter, MD, Antonio Piga, MD, Yongrong Lai, MD, Amal El-Beshlawy, MD, Khawla Beloul, MD, Mohsen Elalfy, MD, Akif Yesilipek, MD, Yurdanur Kilinç, MD, Tomasz Lawniczek, MD, Dany Habr, MD, Marianne Weisskopf, PhD, Yiyun Zhang, PhD, Yesim Aydinok, MD

Blood (2012) 120 (21): 2124.

https://doi.org/10.1182/blood.V120.21.2124.2124

Published: 2012

Journal Articles

Serum Ferritin, Labile Plasma Iron and Transferrin Saturation: Comparison Between Underlying Anemias with Transfusional Iron Overload Before and After Treatment with Deferasirox.

John B Porter, MD, Mohsen Elalfy, MD, Vip Viprakasit, MD, DPhil, Stephane Giraudier, MD, Lee Lee Chan, MD, Yongrong Lai, MD, Ali El-Ali, MD, Nicolas Martin, MS, M Domenica Cappellini, MD

Blood (2012) 120 (21): 2126.

https://doi.org/10.1182/blood.V120.21.2126.2126

Published: 2012

Journal Articles

Elevated Hematocrit Concentration and the Risk of Mortality and Vascular Events in Patients Undergoing Major Surgery.

Khaled M Musallam, John B Porter, MD, Assaad Soweid, Jamal J Hoballah, Pierre M Sfeir, Mohamed Khalife, Salah Zeineldine, Hani M Tamim, Toby Richards, Luca Andrea Lotta, Flora Peyvandi, Faek R Jamali

Blood (2012) 120 (21): 2088.

https://doi.org/10.1182/blood.V120.21.2088.2088

Published: 2012

Journal Articles

Concomitant Medications and Gastrointestinal Events in Thalassemia and MDS Patients Receiving Deferasirox for Transfusional Iron Overload: Data From the EPIC Study

M Domenica Cappellini, MD, Amal El-Beshlawy, MD, John B Porter, MD, Antonis Kattamis, MD, PhD, Kerry Taylor, MD, Christian Rose, Vernon J Louw, MD, Ali El-Ali, MD, Nicolas Martin, MS, Norbert Gattermann, MD

Blood (2012) 120 (21): 5182.

https://doi.org/10.1182/blood.V120.21.5182.5182

Published: 2012

NARROW

Long-Term Dosing in Sickle Cell Disease Subjects with GBT440, a Novel HbS Polymerization Inhibitor

Insights into Relationships Between Serum Ferritin and Liver Iron Concentration Trends during 12 Months of Iron Chelation Therapy with Deferasirox – a Post-Hoc Analysis from the Epic Study

Eltrombopag Mobilizes Intracellular Iron Stores at Concentrations Lower Than Those Required with Other Clinically Available Iron Chelators

Multivariate Analysis Evaluating Potential Predictors of Cardiac T2* Where Cardiac Magnetic Resonance Imaging (CMR) Availability Is Limited

Relative Trends in Myocardial T2* Versus Myocardial Iron Concentration As Representations of Myocardial Iron Chelation Efficacy in Patients with β Thalassemia Major Treated with Deferasirox for up to 3 Years

Modeling Combination Chelation Regimes To Optimize Cellular Iron Removal and Explore Mechanisms Of Enhanced Chelation

Deferasirox Compared With Deferoxamine For The Removal Of Cardiac Iron In Patients With β-Thalassemia Major: 2-Year Data From The Cordelia Extension

Association Of Cardiac Iron By T2* With Innate Immune Markers In Transfusion-Dependent Thalassemia Patients Undergoing Combined Chelation Therapy

Deferasirox–Deferoxamine Combination Therapy Reduces Cardiac Iron With Rapid Liver Iron Removal In Patients With Severe Transfusional Iron Overload (HYPERION)

Determinants Of Tissue Iron Loading In Transfused and Non-Transfused β-Thalassemia and Sickle Cell Disease Patients – Biomarkers Of Iron Regulation and Inflammation

Spinal Artery Thrombosis: An Unrecognized Severe Complication in Thalassemia and Sickle Disorders

Sildenafil Therapy in Patients with Thalassemia and an Elevated Tricuspid Regurgitant Jet Velocity (TRV) On Doppler Echocardiography At Risk for Pulmonary Hypertension: Report From the Thalassemia Clinical Research Network

Innate Immune Cell Expression of Pattern Recognition Receptors From β-Thalassemia Patients During Intensive Combination Chelation Therapy

Deferasirox Continues to Reduce Iron Overload in Non-Transfusion-Dependent Thalassemia: A One-Year, Open-Label Extension to a One-Year, Randomized, Double-Blind, Placebo-Controlled Study (THALASSA)

Metabolomic Biomarkers As Predictors of Iron Load and Oxidative Damage in Iron Overloaded Thalassemia Patients

Cardiopulmonary and Laboratory Profiling of Patients with Thalassemia At Risk for Pulmonary Hypertension: Report From the Thalassemia Clinical Research Network.

A Multicenter, Randomized, Open-Label Trial Evaluating Deferasirox Compared with Deferoxamine for the Removal of Cardiac Iron in Patients with β-Thalassemia Major and Iron Overload (CORDELIA).

Serum Ferritin, Labile Plasma Iron and Transferrin Saturation: Comparison Between Underlying Anemias with Transfusional Iron Overload Before and After Treatment with Deferasirox.

Elevated Hematocrit Concentration and the Risk of Mortality and Vascular Events in Patients Undergoing Major Surgery.

Concomitant Medications and Gastrointestinal Events in Thalassemia and MDS Patients Receiving Deferasirox for Transfusional Iron Overload: Data From the EPIC Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only